Physician profile
Amy Randall
NPI 1164723219
$1,660.30
in general payments reported to CMS, 2019-2025
29 companies · $18.56 in 2025
The $18.56 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $628 · 2023: $671 · 2025: $18.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.75 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.89 | 2021-2023 | |
| Amgen INC. | $152.96 | 2021-2023 | Kyprolis, Blincyto, Lumakras |
| Seagen INC. | $152.29 | 2022-2023 | Tivdak |
| Daiichi Sankyo INC. | $152.18 | 2021-2023 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $152.16 | 2021-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $134.52 | 2022-2023 | Keytruda, Lynparza |
| Genentech USA, INC. | $108.93 | 2021-2023 | Phesgo |
| Astellas Pharma US INC | $89.95 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $54.06 | 2021-2023 | Bevespi Aerosphere |
| Lilly USA, LLC | $48.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $44.43 | 2021-2022 | |
| Pfizer INC. | $42.63 | 2021 | |
| Janssen Biotech, INC. | $41.44 | 2022 | |
| Myovant Sciences INC. | $37.14 | 2022 | |
| Jazz Pharmaceuticals INC. | $36.53 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $23.06 | 2022 | |
| Sobi, INC | $20.99 | 2023 | |
| Genzyme Corporation | $20.87 | 2023 | |
| Abbvie INC. | $18.56 | 2025 | |
| Mirati Therapeutics, INC. | $18.54 | 2023 | Krazati |
| Celgene Corporation | $18.38 | 2022 | |
| Tersera Therapeutics LLC | $17.46 | 2021 | |
| Stemline Therapeutics INC. | $15.40 | 2023 | Orserdu |
| Blueprint Medicines Corporation | $15.38 | 2021 | |
| Dova Pharmaceuticals | $15.20 | 2021 | |
| Gilead Sciences, INC. | $14.12 | 2023 | |
| G1 Therapeutics, INC. | $14.02 | 2022 | |
| Eisai INC. | $12.39 | 2022 | |
| Morphosys, US INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.